Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California

Yu-Jui Yvonne Wan, R. E. Poland, G. Han, T. Konishi, Y. P. Zheng, N. Berman, K. M. Lin

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African-American populations. In order to bridge this gap, we examined the genotype and phenotype of the enzyme in 154 African-American (AA) and 143 Caucasian (C) normal volunteers. AAs are significantly more likely to possess *17 and *5, but less likely to have *4. Overall, the two groups were similar in their CYP2D6 activity as measured with dextromethorphan as the probe (metabolic ratio 2.21 ± 0.78 for AAs; 2.11 ± 0.86 for Cs; t = 1.02, NS). Two of four AAs and six of seven Cs were classified as poor metabolizers and have two nonfunctioning alleles. CYP2D6 activity is determined by *17, *4, *5 and age in AAs (r2 = 0.33, f = 18.8, P < 0.001) and by *4 and *XN in Cs (r2 = 0.14, f = 10.8, P < 0.001). These results support previous findings demonstrating the importance of *17 in determining CYP2D6 activity in AAs.

Original languageEnglish (US)
Pages (from-to)489-499
Number of pages11
JournalPharmacogenetics
Volume11
Issue number6
DOIs
StatePublished - 2001

Fingerprint

Cytochrome P-450 CYP2D6
African Americans
Enzymes
Genes
Dextromethorphan
Disease Susceptibility
Genetic Polymorphisms
Healthy Volunteers
Alleles
Genotype
Phenotype
Pharmaceutical Preparations
Population

Keywords

  • African-American
  • CYP2D6
  • Dextromethorphan
  • Polymorphism

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. / Wan, Yu-Jui Yvonne; Poland, R. E.; Han, G.; Konishi, T.; Zheng, Y. P.; Berman, N.; Lin, K. M.

In: Pharmacogenetics, Vol. 11, No. 6, 2001, p. 489-499.

Research output: Contribution to journalArticle

Wan, Yu-Jui Yvonne ; Poland, R. E. ; Han, G. ; Konishi, T. ; Zheng, Y. P. ; Berman, N. ; Lin, K. M. / Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. In: Pharmacogenetics. 2001 ; Vol. 11, No. 6. pp. 489-499.
@article{20eacdb928414cb2a510b887dc4772c8,
title = "Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California",
abstract = "Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African-American populations. In order to bridge this gap, we examined the genotype and phenotype of the enzyme in 154 African-American (AA) and 143 Caucasian (C) normal volunteers. AAs are significantly more likely to possess *17 and *5, but less likely to have *4. Overall, the two groups were similar in their CYP2D6 activity as measured with dextromethorphan as the probe (metabolic ratio 2.21 ± 0.78 for AAs; 2.11 ± 0.86 for Cs; t = 1.02, NS). Two of four AAs and six of seven Cs were classified as poor metabolizers and have two nonfunctioning alleles. CYP2D6 activity is determined by *17, *4, *5 and age in AAs (r2 = 0.33, f = 18.8, P < 0.001) and by *4 and *XN in Cs (r2 = 0.14, f = 10.8, P < 0.001). These results support previous findings demonstrating the importance of *17 in determining CYP2D6 activity in AAs.",
keywords = "African-American, CYP2D6, Dextromethorphan, Polymorphism",
author = "Wan, {Yu-Jui Yvonne} and Poland, {R. E.} and G. Han and T. Konishi and Zheng, {Y. P.} and N. Berman and Lin, {K. M.}",
year = "2001",
doi = "10.1097/00008571-200108000-00004",
language = "English (US)",
volume = "11",
pages = "489--499",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California

AU - Wan, Yu-Jui Yvonne

AU - Poland, R. E.

AU - Han, G.

AU - Konishi, T.

AU - Zheng, Y. P.

AU - Berman, N.

AU - Lin, K. M.

PY - 2001

Y1 - 2001

N2 - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African-American populations. In order to bridge this gap, we examined the genotype and phenotype of the enzyme in 154 African-American (AA) and 143 Caucasian (C) normal volunteers. AAs are significantly more likely to possess *17 and *5, but less likely to have *4. Overall, the two groups were similar in their CYP2D6 activity as measured with dextromethorphan as the probe (metabolic ratio 2.21 ± 0.78 for AAs; 2.11 ± 0.86 for Cs; t = 1.02, NS). Two of four AAs and six of seven Cs were classified as poor metabolizers and have two nonfunctioning alleles. CYP2D6 activity is determined by *17, *4, *5 and age in AAs (r2 = 0.33, f = 18.8, P < 0.001) and by *4 and *XN in Cs (r2 = 0.14, f = 10.8, P < 0.001). These results support previous findings demonstrating the importance of *17 in determining CYP2D6 activity in AAs.

AB - Despite its importance in drug metabolism and disease susceptibility, CYP2D6 activity and genetic polymorphism have rarely been investigated in African-American populations. In order to bridge this gap, we examined the genotype and phenotype of the enzyme in 154 African-American (AA) and 143 Caucasian (C) normal volunteers. AAs are significantly more likely to possess *17 and *5, but less likely to have *4. Overall, the two groups were similar in their CYP2D6 activity as measured with dextromethorphan as the probe (metabolic ratio 2.21 ± 0.78 for AAs; 2.11 ± 0.86 for Cs; t = 1.02, NS). Two of four AAs and six of seven Cs were classified as poor metabolizers and have two nonfunctioning alleles. CYP2D6 activity is determined by *17, *4, *5 and age in AAs (r2 = 0.33, f = 18.8, P < 0.001) and by *4 and *XN in Cs (r2 = 0.14, f = 10.8, P < 0.001). These results support previous findings demonstrating the importance of *17 in determining CYP2D6 activity in AAs.

KW - African-American

KW - CYP2D6

KW - Dextromethorphan

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=0034891594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034891594&partnerID=8YFLogxK

U2 - 10.1097/00008571-200108000-00004

DO - 10.1097/00008571-200108000-00004

M3 - Article

VL - 11

SP - 489

EP - 499

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 6

ER -